Dong-A Socio Holdings
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Dong-A Socio Holdings
As the global economy remains in a slump, even big pharmas such as Novartis and Pfizer are cutting costs. So how should Korean biopharmas adapt to such an environment and move ahead? Korea Drug Development Fund CEO H. Samuel Muk provides some ideas on how domestic players can survive in this new global reality.
Hopes are rising that Johnson & Johnson will be able to emulate AbbVie’s success in delaying US biosimilar competition to its top-selling Humira by using a similar settlement strategy with its anti-IL12/IL23 blockbuster Stelara.
Dong-A ST’s president of R&D Jae-Hong Park talks to Scrip about the changes needed in the domestic pharma sector and wider industry if Korean biopharma firms are to step up to global levels.
KIMCo CEO Kevin Kyunghwa Huh talks about the consortium's efforts to become a platform of collaboration for Korean pharmas, including plans for the latest joint investment project as well as how the domestic industry is evolving in terms of globalization and open innovation.
- In Vitro Diagnostics
- Medical Devices
- Drug Delivery
- OTC, Consumer
In Vitro Diagnostics
- Chemistry, Immunoassay
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Dong-A Pharmaceutical Co., Ltd (Dong-A Pharm)
- Dong-A Science Technology Co., Ltd (Dong-A ST)
- Dong-A Socio Group
- JCOM Co. Ltd.
- Mezzion Co. Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.